Journal article
Diagnostic Testing for Lyme Disease
Infectious disease clinics of North America, Vol.36(3), pp.605-620
09/01/2022
DOI: 10.1016/j.idc.2022.04.001
PMID: 36116838
Abstract
Standard 2-tier testing (STTT), incorporating a screening enzyme immunoassay (EIA) or an immunofluorescence assay (IFA) that reflexes to IgM and IgG immunoblots, has been the primary diagnostic test for Lyme disease since 1995. In 2019, the Food and Drug Administration approved a modified 2-tier test strategy using 2 EIAs: offering a faster, less expensive, and more sensitive assay compared with STTT. New technologies examine early immune responses to Borrelia burgdorferi have the potential to diagnose Lyme disease in the first weeks of infection when existing serologic testing is not recommended due to low sensitivity.
Details
- Title: Subtitle
- Diagnostic Testing for Lyme Disease
- Creators
- Takaaki Kobayashi - University of Iowa Hospitals and ClinicsPaul G. Auwaerter - Johns Hopkins University
- Resource Type
- Journal article
- Publication Details
- Infectious disease clinics of North America, Vol.36(3), pp.605-620
- Publisher
- Elsevier
- DOI
- 10.1016/j.idc.2022.04.001
- PMID
- 36116838
- ISSN
- 0891-5520
- eISSN
- 1557-9824
- Number of pages
- 16
- Language
- English
- Date published
- 09/01/2022
- Academic Unit
- Infectious Diseases; Internal Medicine
- Record Identifier
- 9984359856202771
Metrics
6 Record Views